Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates

Gynecologic Oncology

Volumn 76, Issue 3, 2000, Pages 397-404

  Molpus, Kelly L ^a   Hamblin, Michael R ^a   Rizvi, Imran ^a   Hasan, Tayyaba ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; PHOTOSENSITIZING AGENT; TALAPORFIN;

ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; XENOGRAFT;

EID: 0034015596     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5705     Document Type: Article

References (47)

1. Parker S E, Tong T, Bolden S, Wingo P A. Cancer statistics 1996. CA Cancer J Clin. 46:1996;5-28.
2. Berek J S, Bertelsen K, du Bois A, Brady M F, Carmichael J, Eisenhauer E A, Gore M, Grenman S, Hamilton T C, Hansen S W, Harper P G, Horvath G, Kaye S B, Luck H J, Lund B, McGuire W P, Neijt J P, Ozols R F, Parmar M K, Piccart-Gebhart M J, van Rijswijk R, Rosenberg P, Rustin G J, Sessa C, Thigpen J T, Trope C, Tuxen M K, Vergote I, Vermorken J B, Willemse P H. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol. 10:1999;S87-S92.
3. McNeil C. Ovarian cancer: Latest gains establish new battlefronts. J Natl Cancer Inst. 87:1995;871-873.
4. Hasan T, Parrish J A. Photodynamic therapy of cancer. Holland J F, Frei E, Bast R C. Cancer Medicine. 1996;739-751 Williams & Wilkins, Baltimore.
5. Hamblin M R, Newman E L. On the mechanism of the tumour-localising effect in photodynamic therapy. J Photochem Photobiol B. 23:1994;3-8.
6. Dougherty T J, Gomer C J, Henderson B W, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst. 90:1998;889-905.
7. Henderson B W, Dougherty T J. How does photodynamic therapy work. Photochem Photobiol. 55:1992;145-157.
8. Markman M. Intraperitoneal chemotherapy in the treatment of ovarian cancer. Ann Med. 28:1996;293-296.
9. Tochner Z, Mitchell J B, Harrington F S, Smith P, Russo D T, Russo A. Treatment of murine intraperitoneal ovarian ascitic tumor with hematoporphyrin derivative and laser light. Cancer Res. 45:1985;2983-2987.
10. Tochner Z, Mitchell J B, Smith P, Harrington F, Glatstein E, Russo D, Russo A. Photodynamic therapy of ascites tumours within the peritoneal cavity. Br J Cancer. 53:1986;733-736.
11. Sindelar W F, DeLaney T F, Tochner Z, Thomas G F, Dachowski L J, Smith P D, Friauf W S, Cole J W, Glatstein E. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms: Phase I study. Arch Surg. 126:1991;318-324.
12. DeLaney T F, Sindelar W F, Tochner Z, Smith P D, Friauf W S, Thomas G, Dachowski L, Cole J W, Steinberg S M, Glatstein E. Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys. 25:1993;445-457.
13. Goff B A, Bamberg M, Hasan T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res. 51:1991;4762-4767.
14. Schmidt S, Wagner U, Schultes B, Oehr P, Decleer W, Ertmer W, Lubaschowski H, Biersack H J, Krebs D. Photodynamic laser therapy with antibody-bound dyes: A new procedure in therapy of gynecologic malignancies. Fortschr Med. 110:1992;298-301.
15. Schmidt S, Wagner U, Oehr P, Krebs D. Clinical use of photodynamic therapy in gynecologic tumor patients: Antibody-targeted photodynamic laser therapy as a new oncologic treatment procedure. Zentralbl Gynakol. 114:1992;307-311.
16. Hasan T, Lin C W, Lin A. Laser-induced selective cytotoxicity using monoclonal antibody-chromophore conjugates. Prog Clin Biol Res. 288:1989;471-477.
17. Goff B A, Bamberg M, Hasan T. Experimental photodynamic treatment of ovarian carcinoma cells with immunoconjugates. Antibody Immunoconj Radiopharm. 5:1992;191-199.
18. Goff B A, Hermanto U, Rumbaugh J, Blake J, Bamberg M, Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer. 70:1994;474-480.
19. Goff B A, Blake J, Bamberg M P, Hasan T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer. 74:1996;1194-1198.
20. Bast R C Jr, Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 68:1981;1331-1337.
21. Hosono M N, Endo K, Sakahara H, Watanabe Y, Saga T, Nakai T, Hosono M, Nakajima T, Onoyama Y, Konishi J. Different antigenic nature in apparently healthy women with high serum CA 125 levels compared with typical patients with ovarian cancer. Cancer. 70:1992;2851-2856.
22. Hamblin M R, Miller J L, Hasan T. The effect of charge on the interaction of site-specific photosensitizer immunoconjugates with human ovarian cancer cells. Cancer Res. 56:1996;5205-5210.
23. 2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br J Cancer. 75:1997;837-844.
24. Louie K G, Hamilton T C, Winker M A, Behrens B C, Tsuruo T, Klecker R W Jr, McKoy W M, Grotzinger K R, Myers C E, Young R C, Oxols R F. Adriamycin accumulation and metabolism in Adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem Pharmacol. 35:1986;467-472.
25. Molpus K L, Koelliker D, Atkins L, Kato D, Buczek-Thomas J, Fuller A FJ, Hasan T. Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer. 67:1996;588-595.
26. Molpus K L, Kato D, Hamblin M R, Lilge L, Bamberg M, Hasan T. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res. 56:1996;1075-1082.
27. Lilge L, Molpus K, Hasan T, Wilson B C. Light dosimetry for intraperitoneal photodynamic therapy in a murine xenograft model of human epithelial ovarian carcinoma. Photochem Photobiol. 68:1998;281-288.
28. Pardridge W M, Bickel U, Buciak J, Yang J, Diagne A, Aepinus C. Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. Immunol Lett. 42:1994;191-195.
29. Basu S K, Goldstein J L, Anderson G W, Brown M S. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci USA. 73:1976;3178-3182.
30. Wang Y M, Evans B, Thomas J H, Nunan T, Gaunt J I, Morris R W, Davies D R. Endocytosis of cationized horseradish peroxidase by glomerular epithelial cells is reduced in puromycin glomerulopathy. Int J Exp Pathol. 71:1990;823-834.
31. Akhlynina T V, Jans D A, Rosenkranz A A, Statsyuk N V, Balashova I Y, Toth G, Pavo I, Rubin A B, Sobolev A S. Nuclear targeting of chlorin e6 enhances its photosensitizing activity. J Biol Chem. 272:1997;20328-20331.
32. Soukos N S, Hamblin M R, Hasan T. The effect of charge on cellular uptake and phototoxicity of polylysine chlorin(e6) conjugates. Photochem Photobiol. 65:1997;723-729.
33. Krinick N L, Sun Y, Joyner D, Spikes J D, Straight R C, Kopecek J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J Biomater Sci Polym Ed. 5:1994;303-324.
34. Perry R R, Smith P D, Evans S, Pass H I. Intravenous vs intraperitoneal sensitizer: Implications for intraperitoneal photodynamic therapy. Photochem Photobiol. 53:1991;335-340.
35. Veenhuizen R B, Ruevekamp-Helmers M C, Helmerhorst T J, Kenemans P, Mooi W J, Marijnissen J P, Stewart F A. Intraperitoneal photodynamic therapy in the rat: Comparison of toxicity profiles for photofrin and MTHPC. Int J Cancer. 59:1994;830-836.
36. Veenhuizen R B, Ruevekamp M C, Oppelaar H, Ransdorp B, van de Vijver M, Helmerhorst T J, Kenemans P, Stewart F A. Intraperitoneal photodynamic therapy: Comparison of red and green light distribution and toxicity. Photochem Photobiol. 66:1997;389-395.
37. Hong G, Bazin-Redureau M I, Scherrmann J MG. Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. J Pharm Sci. 88:1999;147-153.
38. Bergmann P, Kacenelenbogen R, Vizet A. Plasma clearance, tissue distribution and catabolism of cationized albumins with increasing isoelectric points in the rat. Clin Sci. 67:1984;35-43.
39. Kornguth S, Lohmiller S, Kalinke T, Robins H I, Kyritsis A, Turski P, Cohen J, Nickles R J, DeJesus O. Biodistribution of polylysine-guided radionuclides. Epenetos A. Monoclonal Antibodies. 1991;133-147 Chapman & Hall Medical, London.
40. Hofer S O, Molema G, Hermens R A, Wanebo H J, Reichner J S, Hoekstra H J. The effect of surgical wounding on tumour development. Eur J Surg Oncol. 25:1999;231-243.
41. Korbelik M, Dougherty G J. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res. 59:1999;1941-1946.
42. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 137:1999;91-98.
43. Cheong W F, Prahi S A, Welch A J. A review of the optical properties of biological tissue. IEEE J Quantum Electronics. 26:1990;2166-2185.
44. Wilson B C. Photodynamic therapy: Light delivery and dosage for second-generation photosensitizers. Ciba Found Symp. 146:1989;60-73.
45. Evrard S, Aprahamian M, Marescaux J. Intra-abdominal photodynamic therapy: From theory to feasibility. Br J Surg. 80:1993;298-303.
46. Lilge L, Dabrowski W, Holdsworth D, Blake J, Kato D, Wilson B, Hasan T. Light delivery and dosimetry for photodynamic therapy in an ovarian-cancer mouse model. SPIE Proc. 2133:1994;150-161.
47. Duska L R, Hamblin M R, Miller J L, Hasan T. Combination photoimmunotherapy and cisplatin: Effects on human ovarian cancer ex vivo. J Natl Cancer Inst. 91:1999;1557-1563.